Series B is where a medtech company has to show it can move from an interesting product to an investable business. The round is less about raising more money than about showing that the milestones funded by the prior round have reduced the next stage's risk enough to justify a larger investment.
Series B diligence tends to look past regulatory progress to operating evidence: whether the company can make, sell and support the product at a larger scale.
Regulatory Progress Beyond the First Authorization
A first 510(k) clearance or other authorization is usually a starting point rather than the whole story. Investors often look for evidence of commercial pull after authorization (customer wins, not just letters of intent), a regulatory pipeline for follow-on products, and a credible path to indication expansion or approvals outside the US.
Clinical Evidence at Scale
Data supporting the lead indication is necessary but not sufficient. A Series B case is stronger with real-world data emerging after launch, comparative effectiveness data against standard of care, and an evidence plan for the indications the new capital is meant to pursue.
Commercial Traction
Signals worth documenting: paying customers with documented use cases; gross margin improving as manufacturing scales; sales productivity consistent with the sales model; documented reasons for lost deals; and expansion within early accounts. The trend and the unit economics often say more than the absolute revenue number.
Manufacturing and Quality Maturity
Since February 2, 2026, FDA's Quality Management System Regulation (21 CFR Part 820) has incorporated ISO 13485:2016 by reference, so a finished device manufacturer's quality system has to meet that standard; third-party ISO 13485 certification is a separate step. Diligence also looks at manufacturing capacity against the demand the plan assumes, and at single-source exposure for critical components. Gaps found in diligence are usually cheaper to address before the round than after it.
Team Composition
Series A often funds a founder-led team. By Series B, investors typically look for functional leadership: engineering leadership matched to the scale-up challenge, sales leadership whose experience fits the go-to-market model, quality and regulatory leadership with experience of the next regulatory step, and finance leadership with healthcare or medical device experience.
Capital Plan
The raise size should connect to the milestones needed for the next round or for operating cash flow. A plan tied to specific milestones, commercial KPIs and downside scenarios is easier to underwrite than a general runway figure, particularly when, as SVB's H2 2026 healthcare report describes, investors are writing fewer, larger checks and capital is concentrating among fewer companies.
A Series B case is strongest when it shows that prior capital was used efficiently, that the next stage's operational risk has been credibly reduced, and that the team has the leadership depth to execute the plan.